A Study Of Pharmacokinetics, Whole Body And Organ Dosimetry, And Biodistribution Of Fission-Derived Iodine I 131 Tositumomab (BEXXAR®) For Patients With Previously Untreated Or Relapsed Follicular Or Transformed Non-Hodgkin's Lymphoma

This study is currently recruiting participants.

Study NCT00315731 Information provided by GlaxoSmithKline

First Received: April 17, 2006 Last Updated: June 9, 2008 History of Changes

No Study Results Posted for this Study

Study Status:	This study is currently recruiting participants.
Estimated Study Completion Date:	February 2016
Estimated Primary Completion Date:	No date given